Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Pharmacoeconomic analysis in Alzheimer’s disease: What is the impact of diagnostic timing? (CROSBI ID 620269)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Vitezić, Dinko Pharmacoeconomic analysis in Alzheimer’s disease: What is the impact of diagnostic timing? // Neurologia Croatica. Supplement / Šimić, Goran ; Mimica, Ninoslav (ur.). 2014. str. 54-54

Podaci o odgovornosti

Vitezić, Dinko

engleski

Pharmacoeconomic analysis in Alzheimer’s disease: What is the impact of diagnostic timing?

Pharmacoeconomic analysis which includes the cost-effectiveness of treatments for Alzheimer’s disease (AD) is an important issue from the economic and public health perspectives. In the most of European countries antidementive pharmacotherapy is accepted as cost effective according to specific guidelines for different patients groups (mild, moderate, and severe AD). In Croatia the most frequently used antidementive agent in 2013 was memantine (three times more then cholinesterase inhibitors, e.g. donepezil), which is certainly the result of earlier acceptance to National health insurance Drug list (HZZO Drug list), but could also be discussed as diagnosis of patients in later stages of disease. Today’s medical technology can enable the earlier detection of AD (mild cognitive impairment, pre dementia or incipient dementia), which could offer earlier therapeutic intervention. On the other hand, in practice, the majority of patients are not diagnosed in a timely manner. From the clinical as well as from the pharmacoeconomical point of view it is of great importance to determine to what extent the timing of diagnosis and specific therapeutic intervention affects its cost- effectiveness. There is a limited data and very few studies in this field, but according to some models it is shown that therapeutical timing is crucial in determining the economic benefits of a treatment. Better results with cost-effective therapy are directly connected with early diagnosis and AD drug therapy.

Alzheimer’s disease; antidementive drugs; pharmacoeconomic analysis; cost-effectiveness

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

54-54.

2014.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Neurologia Croatica. Supplement

Šimić, Goran ; Mimica, Ninoslav

Zagreb:

1331-5196

Podaci o skupu

Croatian Congress on Alzheimer's Disease (CROCAD-14)

pozvano predavanje

01.10.2014-04.10.2014

Brela, Hrvatska

Povezanost rada

Kliničke medicinske znanosti